Fire in Whitney-Hendrickson Building Impacts Clinic Schedules; Markey Remains Open uky.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uky.edu Daily Mail and Mail on Sunday newspapers.
of
LEXINGTON, Ky. (May 4, 2021) UK HealthCare will begin the programming and design of a new outpatient cancer treatment center and advanced ambulatory complex that also will include other ambulatory services. The design phase of the capital project was approved by the University of Kentucky Board of Trustees’ health care committee on Monday and pending approval by the full Board on Tuesday.
The new complex with an estimated 260,000 square feet for cancer services may include multiple buildings but will primarily allow for the needed expansion of patient care services and increased ease of access for the UK Markey Cancer Center. As the only National Cancer Institute (NCI)-designated center in Kentucky, Markey is able to offer cutting-edge and early phase therapies not available to patients being treated anywhere else in Kentucky.
LEXINGTON,
Ky. (April 27, 2021) – A recent study by University of Kentucky Markey Cancer Center researchers looked into the association of financial burden with health insurance literacy in colorectal cancer patients.
Recently published in Supportive Care in Cancer, the team utilized the Kentucky Cancer Registry data to collect surveys from colorectal cancer survivors in Kentucky to identify if there was a correlation between individuals suffering from financial toxicity and comprehension of health insurance.
Financial toxicity is the accumulation of the financial costs and financial distress or hardship that can affect the health and wellbeing of cancer survivors. Studies cited in the article highlight how survivors suffering from financial toxicity had a poorer quality of life, decreased survival, increased symptom burden, and a decrease in treatment compliance.
Made with artemisia annua plants grown on Kentucky farms, ArtemiLife coffee is now being used in a unique Markey clinical trial.
LEXINGTON, Ky. (April 26, 2021) From Kentucky farms to University of Kentucky labs and now to Kentucky patients, the UK Markey Cancer Center has officially launched a unique new clinical trial to test whether Artemisia annua extract can prevent ovarian cancer recurrence. Markey will be the first site worldwide to initiate a cancer clinical trial that evaluates its anti-cancer activity in humans using ArtemiLife™ Inc. coffee products, which are made using the leaves of the Artemisia annua plant.
Roughly one in every 75 women will develop ovarian cancer, which often spreads beyond the ovary before detection. According to 2020 data estimates from the American Cancer Society, the predicted death rate for ovarian cancer is about 64%.
of
LEXINGTON, Ky. (April 12, 2021) With COVID-19 vaccinations continuing to roll out across the country, the University of Kentucky Markey Cancer Center strongly encourages both cancer survivors, caregivers and patients in active cancer treatment to receive one of the available vaccines. This is in line with recommendations from both the Centers for Disease Control and Prevention (CDC) and the American Cancer Society.
As of Monday, April 5, any Kentuckian age 16 and up is eligible to get the Pfizer vaccine. The Moderna and Johnson & Johnson vaccines are available to anyone age 18 and older. Given the higher rates of severe COVID-19 infection in cancer patients, the American Society of Clinical Oncology and the CDC recommend that cancer patients strongly consider vaccination against COVID-19, said Dr. Frederick R. Ueland, gynecologic oncologist and director of oncology clinical operations at the UK Markey Cancer Center. This includes cancer survivors, most patients undergo